Daix (France), Long Island City (New York, United States), November 21, 2022
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company focused on the clinical development of orally administered small molecules for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with a disaffected physician has, today announces the cooptation of Dr. Lucy Lu announced as a Director on its Board of Directors effective November 9, 2022 in place of Sofinnova Partners.
The appointment of Dr. Lucy Lu will be presented to shareholders for confirmation at the next Inventiva AGM.
dr Lucy Lu is the representative of Sofinnova Partners on the board of Inventiva since January 4, 2020. dr Lu has broad experience of more than 20 years in the biotechnology and healthcare sectors as an investment banker, financial analyst and executive director. dr Lu is Chief Operating Officer at Innovative Cellular Therapeutics and was previously President and CEO of Avenue Therapeutics. dr Lu also worked as a biotechnology financial analyst for Citigroup Inc. and has an MD from
New York University School of Medicine.
Frédéric Cren, Chairman and CEO and co-founder of Inventiva, commented
“We are very pleased, Dr. to appoint Lu as a member of the Inventiva Board of Directors. dr Lu has been on the board for almost three years and his global industry knowledge is a great asset to the company, particularly in the development of Lanifibranor and the signing of an initial licensing agreement for the development and commercialization of Lanifibranor in Greater China. On behalf of the Board of Directors, I would like to thank Dr. Lu for his continued service on the board, and I also thank Sofinnova Partners for their contribution to Inventiva’s success over the past three years. »
Inventiva is a biopharmaceutical company focused on the discovery and development of orally administered small molecules to treat patients with NASH, MPS and other conditions with significant unmet medical needs. The company has extensive experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently developing a clinical candidate, has a portfolio of two pre-clinical programs and continues to evaluate other development opportunities to expand its portfolio.
Lanifibranor, Inventiva’s lead drug candidate, is currently being evaluated in the pivotal Phase III clinical trial NATiV3 for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there is currently no approved treatment.
In 2020, Inventiva announced positive results from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and received designation
” and from ”
Food and Drug Administration
(FDA) for lanifibranor for the treatment of NASH.
Inventiva’s portfolio also includes Odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended its clinical efforts with Odiparcil and is evaluating all available options to optimize its development. Inventiva is in the process of selecting a drug candidate in oncology as part of its program dedicated to the Hippo pathway.
The company has a scientific team of approximately 80 people with extensive expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. Inventiva has a chemical library of around 240,000 molecules, around 60% of which are exclusive to the company, as well as its own laboratories and equipment.
Inventiva is listed in compartment C of the Regulated Market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
Laurence Frost /
Tristan Roquet Montegon /
+33 1 53 96 83 83
Westwicke, an ICR company
Patricia L Bank
+1 415 513-1284
This press release contains forward-looking statements. All statements in this press release, other than statements of historical fact, are forward-looking statements. These statements include, but are not limited to, projections and estimates with respect to Inventiva’s pre-clinical and clinical programs, including recruitment and screening for such clinical trials, including the NATiV3 Phase III clinical trial for the treatment of lanifibranor in NASH, potential Development and regulatory path for Odiparcil, clinical data releases, information, analysis and implications that may be gleaned through clinical trials, therapeutic benefit potential of Lanifibranor, the agreement entered into between the Company and Sino Biopharm, pipeline and preclinical or clinical development plans, future activities, Company expectations, plans, growth and projections, and sufficient liquidity and funding horizon. Some of these statements, forecasts and estimates can be identified by the use of words such as “believes”, “anticipates”, “expects”, “projects”, “plans”, “aims”, “estimates”, “may”, “will” and “continue” and other similar expressions. These statements are not verified historical facts, but instead constitute projections, estimates and other forward-looking information based on management’s opinions, expectations regarding the potential commercial success and potential sales of Inventiva’s drug candidates. These statements reflect the opinions and assumptions expressed at the time they were made. They are subject to known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied by such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva’s control. With respect to the pipeline of product candidates, there can be no assurance that clinical study results will be available as planned, that future clinical studies will commence as planned, or that these candidates will receive necessary regulatory approvals. Actual results could differ from those described, implied or anticipated in such forward-looking statements due to a number of important factors, including the fact that Inventiva is a clinical-stage company with no approved products and no historical revenue the sale of products. These factors include, but are not limited to, Inventiva’s significant losses since inception, limited operating history, lack of revenue from the sale of Inventiva’s products and the need for additional funds to fund operations. Inventiva’s future success also depends on the successful clinical development, receipt of regulatory approvals and subsequent commercialization of its current and future product candidates. Preclinical studies or previous clinical studies are not necessarily predictors of future results, and the results of Inventiva’s clinical studies may not support the reported benefits of Inventiva’s product candidates. Inventiva may experience significant delays in its clinical trials, or Inventiva may fail to demonstrate the safety and efficacy of its products to the appropriate regulatory authorities. Recruiting and retaining patients in clinical trials is a costly and time-consuming process that could be complicated or rendered impossible by several factors beyond Inventiva’s control. Inventiva’s product candidates could have adverse effects or exhibit other properties that could delay or prevent their regulatory approval or limit their commercial potential. The condition and operating results could be affected by the COVID-19 pandemic and geopolitical events such as the conflict between Russia and Ukraine be materially impacted, which could delay or delay the initiation, recruitment and scheduled completion of Inventiva’s clinical trials. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, projections and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this release. Readers are therefore cautioned not to place undue reliance on these forward-looking statements.
We invite you to refer to the Universal Registration Document filed with the Autorité des Marchés Financiers on March 11, 2022 for the year ended December 31, 2021 and the Financial Report for the first half of 2022 for more information on these factors and Obtain risks and uncertainties.
Subject to applicable regulations, Inventiva makes no commitment to update or revise the information contained in this press release. Inventiva can therefore not be held liable
Consequences that may arise from the use of these declarations.
Inventiva – PR – Board of Directors – 11/21/2022